
|Articles|June 4, 2014
The Potentiation of Checkpoint Blockade With Oncolytic Virus
Author(s)James P. Allison, PhD
James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, discusses the potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.
Advertisement
James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, discusses the potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5



































